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Invasive aspergillosis is an important cause of morbidity and mortality in immunocompromised patients. Among
primary immunodefiencies, chronic granulomatous disease (CGD) has the highest prevalence of invasive fungal
diseases. Voriconazole is recommended for the primary treatment of invasive aspergillosis in most patients. In
patients whose aspergillosis is refractory to voriconazole, therapeutic options include changing class of antifungal,
for example using an amphotericin B formulation, an echinocandin, combination therapy, or further use of azoles.
Posaconazole is a triazole derivative which is effective in Aspergillosis prophylaxis and treatment. Rarely, surgical
therapy may be needed in some patients. Lesions those are contiguous with the great vessels or the pericardium,
single cavitary lesion that cause hemoptysis, lesions invading the chest wall, aspergillosis that involves the skin and
the bone are the indications for surgical therapy.
Chronic granulomatous disease (CGD) is an inherited immundeficiency caused by defects in the phagocyte
nicotinamide adenine dinucleotidephosphate (NADPH) oxidase complex which is mainstay of killing
microorganisms. CGD is characterized by recurrent life-threatening bacterial and fungal infections and by
abnormally exuberant inflammatory responses leading to granuloma formation, such as granulomatous enteritis,
genitourinary obstruction, and wound dehiscence. The diagnosis is made by neutrophil function testing and the
genotyping.
Herein, we present a case with CGD who had invasive pulmonary aspergillosis refractory to voriconazole and
liposomal amphotericine B combination therapy that was controlled with posaconazole treatment and pulmonary
surgery.
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Chronic granulomatous disease (CGD) is a rare inherited
phagocytic disorder that results in an increased susceptibility
to bacterial and fungal infections and granulomatous compli-
cations [1,2]. CGD is characterized by the inability of phago-
cytes (neutrophils, monocytes, macrophages) to produce
reactive oxygen species due to the absence or dysfunction of
the NADPH complex [2,3]. The aberrant phagocyte function* Correspondence: asoysal@marmara.edu.tr
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stated.characteristic of CGD increases susceptibility to infection to
catalase-positive organisms (e.g., Nocardia, Aspergillus, Ser-
ratia etc.). Hematopoietic stem cell transplantation is the
only known cure for CGD [4,5]. Antimicrobial prophylaxis
with trimethoprim-sulfamethoxazole and itraconazole re-
duces infectious complications. Supportive treatment with
interferon gamma results in better outcomes in a subgroup
of variant X linked CGD patients but its routinely usage in
CGD patients remains controversial [2,6].
Aspergillus species are ubiquitous in nature, and inhalation
of infectious conidia is a frequent event. Tissue invasion is
uncommon and occurs in the setting of immunosuppression.
Invasive aspergillosis is an important cause of morbidity andral Ltd. This is an Open Access article distributed under the terms of the Creative
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primary immunodefiencies, CGD has the highest prevalence
of invasive fungal diseases estimated between 20% and 40%
per patient throughout their entire life [11,12]. Invasive fun-
gal disease occurs mostly during the first 2 decades, but neo-
natal cases have also been reported [13]. The most common
fungal genus involved is Aspergillus and lungs are the most
frequent localization. The diagnosis is made by fungal culture
of tissues or body fluids, pathological examination of affected
organs, radiological findings consistent with fungal lesions
(e.g., halo sign and air-crescent sign), fungal antigen assays
(galactomannan and beta-1,3-D-glucan) [14]. Therapeutic
options include azole derivatives, echinocandins and ampho-
tericin B, but voriconazole is recommended as the first-line
therapy [14]. Although diagnostic and therapeutic interven-
tions improved in last decades many patients usually requires
salvage therapy [14]. In patients whose aspergillosis is refrac-
tory to voriconazole, therapeutic options include a change of
class using an amphotericin B formulation or an echinocan-
din, further use of azoles. Salvage treatment with posacona-
zole have been shown to be safe and effective [15,16].
Herein, we present a case with CGD who had invasive
pulmonary aspergillosis refractory to voriconazole and
lipozomal amphotericine B combination therapy that
was controlled with posaconazole treatment and pul-
monary surgery.
Case
A 30 month-old boy presented with fever, cough, swelling
and purulent discharge on upper part of his back consist-
ent with abscess formation. Fungal culture from this ab-
scess yielded Aspergillus spp. that was susceptible to
voriconazole and amphotericin B but resistant to caspo-
fungin. Voriconazole was given as initial monotherapy andFigure 1 Computerized tomography findings consistent with expansithen combined with liposomal amphotericin B because of
progression of the lesions detected on computerized tom-
ography (CT). Diagnosis of CGD was suggested by the
presence of CGD history in the mother’s family and an
extraordinary pathogen existence in the fungal culture of
the abcess. The diagnosis was confirmed with the nitro-
blue tetrazolium and dihidro-rhodamin oxidase assay. He
was defined as X-linked CGD and gp91 CYBB gene, exon7
c.742dupA,p.Ile248AsnfsX36 molecule was defective.
Interferon gamma and trimethoprim-sulfamethoxasole
were given for supportive care and antimicrobial prophy-
laxis. Constriction of the right bronchie, consolidation of
the right upper lobe including air broncograms and fistuli-
zation to the skin was detected in thorax CT (Figure 1).
Antifungal combination therapy with voriconazole and
amphotericin B was given for six months but the lesions
did not regress and caused costal bone destruction. He
underwent chest surgery and his destroyed right upper
pulmonary lobe, upper segment of the lower lobe, two
necrotic costal bones and the tract of the fistula were
resected. Vertical fungal hyphaes, supurative granuloma-
tous inflamation, fibrosis, destruction of the bone trabecu-
las in PAS and silver staining of surgical resection
specimens were observed in pathological examination
(Figure 2). Antifungal treatment was continued with
posaconazole monotherapy right after surgery. Hepatic
transaminase levels, serum electrolyte levels, erythrocyte
sedimentation rate, C-reactive protein, complete blood
count, electrocardiography (ECG) monitorized in monthly
period and all were normal. Serum galactomannan antigen
was 2,09 and positive right before surgery, then it was nega-
tive repeatedly. Thorax CT was repeated in every six
months. In the thirty-six months follow up since from pul-
monary surgery to date, no any complaints or fungalve pulmonary involvement.
Figure 2 Vertical fungal hyphaes in PAS and silver staining of
the lung resection specimens.
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zole therapy was given continuously (Figure 3).
Conclusions
Galactomannan, a major constituent of Aspergillus cell walls
that is released during the growth of hyphae, can usually be
detected by enzyme immunoassay in serum, bronchoalveo-
lar lavage fluid, cerebrospinal fluid, and pleural fluid [14].
But galactomannan is quite insensitive, even in the setting
of proven infection in CGD [12]. In our patient galactoman-
nan antigen was positive only for once before surgery and
posaconazole therapy, then it was negative repeatedly.
Voriconazole is the primary therapy option for invasive
pulmonary aspergillosis. Alternative therapies are liposomal
and lipid complex amphotericin B, echinocandins and otherFigure 3 Thorax computerized tomography imaging which is
not containing fungal lesions after surgery and
posaconazole theraphy.azole derivatives such as posaconazole and itraconazole.
The oral bioavailability of the azole derivatives is an advan-
tage for the maintenance therapy after initial therapy [14].
Posaconazole is an extended spectrum triazole with invivo
and invitro activity against Aspergillus species but dosage in
pediatric patients has not been defined [14-16]. The posa-
conazole releated side effects are nausea, vomiting, an-
orexia, abdominal pain, dehidratation, fever, rash, throat
and chest pain, headache, blurred vision and sleeplessness.
The patient should be monitored for liver transaminase
elevation, hypocalcemia, hypomagnesemia, hypokalemia,
hyperglycemia, pancytopenia, hypertension, hypotension
and, cardiac rhythm abnormalities such as QT interval pro-
longation [14-16]. Posaconazole was given 200 mg 4 times
a day with meals to our patient right after the surgery. He
received posaconazole for 36 months without any side
effects.
Surgery may be useful in lesions that are contiguous
with the great vessels or the pericardium, single cavitary
lesion that cause hemoptysis, lesions invading the chest
wall or in aspergillosis that involves the skin and the
bone. Surgical resection of devitalized bone and cartilage
is important for curative intent [14]. In our patient,
destroyed right upper pulmonary lobe, upper segment of
the right lower lobe, two necrotic costal bones and the
tract of the fistula were resected, when disease progres-
sion was observed during the combined antifungal
therapy.
In conclusion, we think, resection of the nonfunctional
pulmonary parenchyma and devitalized bone and carti-
lages increased the success of posaconazole maintenance
therapy.Consent
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